The key for EDRN's success lies in good communication among scientists in multiple disciplines; efficient evaluation and prioritization of promising biomarkers; and rigorous validation studies to demonstrate their clinical utility. The overall aims of the proposed renewal of the Data Management and Coordinating Center (DMCC) are to (i) provide coordination of EDRN in order to enhance communication and collaboration among EDRN investigators and with general scientific communities; (ii) provide statistical support to evaluate and prioritize promising biomarkers, and (iii) coordinate EDRN validation studies. Under the direction of the Steering Committee, the DMCC will 1) perform network coordination and promote collaborations among scientific investigators by providing support for EDRN meetings and workshops, developing and maintaining EDRN public and secure websites and listservs, producing and maintaining all EDRN documents, and maintaining the online review system for applications submitted to the EDRN; 2) support EDRN validation studies by developing and maintaining validation study data management systems; working with EDRN investigator on study design, protocol development, data forms, and study manuals; coordinating and monitoring studies; tracking specimens; and performing QA/QC and study evaluation; 3) provide statistical services to EDRN; 4) develop methodologies and computational tools needed by EDRN for biomarker discovery and validation, including developing methods for a) preprocessing high dimensional proteomic and genomic data; b) selecting and prioritizing biomarkers from high dimensional data; c) combining multiple biomarkers for clinical tests; d) addressing population heterogeneity; and e) designing studies efficiently; and 5) work with NCI and JPL to provide informatic resources for the EDRN Secure Web site for data security, data warehouse, and data sharing, and a Public Website for dissemination. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA086368-08
Application #
7235717
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J2))
Program Officer
Wagner, Paul D
Project Start
2000-04-14
Project End
2010-02-28
Budget Start
2007-03-01
Budget End
2008-02-29
Support Year
8
Fiscal Year
2007
Total Cost
$1,900,673
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Tayob, Nabihah; Stingo, Francesco; Do, Kim-Anh et al. (2018) A Bayesian screening approach for hepatocellular carcinoma using multiple longitudinal biomarkers. Biometrics 74:249-259
Liu, Dandan; Cai, Tianxi; Lok, Anna et al. (2018) Nonparametric Maximum Likelihood Estimators of Time-Dependent Accuracy Measures for Survival Outcome Under Two-Stage Sampling Designs. J Am Stat Assoc 113:882-892
Fu, Rong; Wang, Pei; Ma, Weiping et al. (2017) A statistical method for detecting differentially expressed SNVs based on next-generation RNA-seq data. Biometrics 73:42-51
Zheng, Yingye; Brown, Marshall; Lok, Anna et al. (2017) IMPROVING EFFICIENCY IN BIOMARKER INCREMENTAL VALUE EVALUATION UNDER TWO-PHASE DESIGNS. Ann Appl Stat 11:638-654
Maziarz, Marlena; Heagerty, Patrick; Cai, Tianxi et al. (2017) On longitudinal prediction with time-to-event outcome: Comparison of modeling options. Biometrics 73:83-93
Zhou, Qian M; Dai, Wei; Zheng, Yingye et al. (2017) Robust Dynamic Risk Prediction with Longitudinal Studies. Stat Theory Relat Fields 1:159-170
Kundu, Madan G; Harezlak, Jaroslaw; Randolph, Timothy W (2016) Longitudinal Functional Models with Structured Penalties. Stat Modelling 16:114-139
Tretiakova, M S; Wei, W; Boyer, H D et al. (2016) Prognostic value of Ki67 in localized prostate carcinoma: a multi-institutional study of >1000 prostatectomies. Prostate Cancer Prostatic Dis 19:264-70
Koopmeiners, Joseph S; Feng, Ziding (2016) Group sequential testing of the predictive accuracy of a continuous biomarker with unknown prevalence. Stat Med 35:1267-80
Huang, Ying; Laber, Eric (2016) Personalized Evaluation of Biomarker Value: A Cost-Benefit Perspective. Stat Biosci 8:43-65

Showing the most recent 10 out of 90 publications